CN102256617B - 膜联蛋白及其治疗炎性病症的用途 - Google Patents

膜联蛋白及其治疗炎性病症的用途 Download PDF

Info

Publication number
CN102256617B
CN102256617B CN200980150927.0A CN200980150927A CN102256617B CN 102256617 B CN102256617 B CN 102256617B CN 200980150927 A CN200980150927 A CN 200980150927A CN 102256617 B CN102256617 B CN 102256617B
Authority
CN
China
Prior art keywords
annexin
sepsis
tnf
lps
inflammatory
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN200980150927.0A
Other languages
English (en)
Chinese (zh)
Other versions
CN102256617A (zh
Inventor
冯清平
陆湘如
保罗·阿诺德
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
London Health Sciences Centre Research Inc
Original Assignee
London Health Sciences Centre Research Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42106169&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN102256617(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by London Health Sciences Centre Research Inc filed Critical London Health Sciences Centre Research Inc
Publication of CN102256617A publication Critical patent/CN102256617A/zh
Application granted granted Critical
Publication of CN102256617B publication Critical patent/CN102256617B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN200980150927.0A 2008-10-17 2009-10-16 膜联蛋白及其治疗炎性病症的用途 Active CN102256617B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US10639008P 2008-10-17 2008-10-17
US61/106,390 2008-10-17
PCT/CA2009/001469 WO2010043045A1 (en) 2008-10-17 2009-10-16 Annexin and its use to treat inflammatory disorders

Publications (2)

Publication Number Publication Date
CN102256617A CN102256617A (zh) 2011-11-23
CN102256617B true CN102256617B (zh) 2015-04-08

Family

ID=42106169

Family Applications (1)

Application Number Title Priority Date Filing Date
CN200980150927.0A Active CN102256617B (zh) 2008-10-17 2009-10-16 膜联蛋白及其治疗炎性病症的用途

Country Status (6)

Country Link
US (1) US9192649B2 (enExample)
EP (1) EP2349321B1 (enExample)
JP (1) JP5590621B2 (enExample)
CN (1) CN102256617B (enExample)
CA (1) CA2740557C (enExample)
WO (1) WO2010043045A1 (enExample)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5590621B2 (ja) 2008-10-17 2014-09-17 ロンドン ヘルス サイエンシーズ センター リサーチ インコーポレイテッド 炎症性障害の処置を処置するためのアネキシンおよびその使用
EP2380023A2 (en) 2008-12-19 2011-10-26 Medirista Biotechnologies AB Oxidized cardiolipin as a novel pro-inflammatory factor
WO2011160845A2 (en) 2010-06-24 2011-12-29 Medirista Biotechnologies Ab Oxidized phospholipids and lipoproteins, and antibodies thereto, as biomarkers of inflammatory conditions and methods of treatment
CN102690345B (zh) * 2011-03-24 2014-03-19 江苏靶标生物医药研究所有限公司 人膜联蛋白v变体及其表达、制备和应用
PL2720707T3 (pl) * 2011-06-15 2019-06-28 Resother Pharma Aps Przeciwzapalne produkty farmaceutyczne
WO2013124327A1 (en) 2012-02-21 2013-08-29 Institut National De La Sante Et De La Recherche Medicale (Inserm) Tim receptors as virus entry cofactors
WO2013124324A1 (en) 2012-02-21 2013-08-29 Institut National De La Sante Et De La Recherche Medicale (Inserm) Tam receptors as virus entry cofactors
WO2014077575A1 (ko) * 2012-11-13 2014-05-22 다인바이오 주식회사 덱에이 효소반응으로 조제한 항비만 및 항당뇨 효능을 갖는 한천 유래 네오아가로올리고당 복합 조성물
GB2542391A (en) * 2015-09-17 2017-03-22 Annexin Pharmaceuticals Ab Process of manufacture
GB201702144D0 (en) * 2017-02-09 2017-03-29 Annexin Pharmaceuticals Ab Therapeutic compositions
WO2019238550A1 (en) * 2018-06-12 2019-12-19 Universiteit Maastricht Method for the treatment of hypoxic-ischemic encephalopathy in newborns
CN109529017B (zh) * 2018-12-25 2022-06-14 江苏靶标生物医药研究所有限公司 一种膜联蛋白v的应用
US11357823B2 (en) * 2019-08-30 2022-06-14 Suzhou Yabao Pharmaceutical R&D Co., Ltd Method for treating cerebral stroke
US20220193192A1 (en) * 2019-08-30 2022-06-23 Suzhou Yabao Pharmaceutical R&D Co Ltd Methods of treating a traumatic brain injury
CN112057623A (zh) * 2020-06-03 2020-12-11 江苏靶标生物医药研究所有限公司 一种磷脂酰丝氨酸在制备治疗炎症性肠病药物中的应用
US20230374091A1 (en) * 2020-10-09 2023-11-23 London Health Sciences Centre Research Inc. Annexin a5 compositions and methods
CN112618696B (zh) * 2020-12-14 2023-05-05 南京大学 Annexin A5在制备治疗胆汁淤积药物中的应用
CN115245559A (zh) * 2021-04-25 2022-10-28 上海萨美细胞技术有限公司 一种用于治疗肺损伤的药物
CN117186239A (zh) * 2022-01-30 2023-12-08 南京瑞初医药有限公司 融合蛋白及其应用
CN118001375A (zh) * 2023-04-12 2024-05-10 上海萨美细胞技术有限公司 一种用于难愈性创面修复的药物
CN119097689A (zh) * 2023-06-08 2024-12-10 上海萨美细胞技术有限公司 一种用于治疗卵巢功能不全的药物
CN118001372A (zh) * 2023-07-04 2024-05-10 上海萨美细胞技术有限公司 膜联蛋白在抗衰老中的用途
CN119158000B (zh) * 2023-10-25 2025-07-18 上海萨美细胞技术有限公司 一种用于治疗肺纤维化的药物
WO2025129329A1 (en) * 2023-12-23 2025-06-26 London Health Sciences Centre Research Inc. Methods for treatment of sepsis
CN118203650B (zh) * 2024-01-26 2025-04-29 上海萨丽斐生物科技有限公司 一种用于治疗色素沉着的药物
CN118846001B (zh) * 2024-07-09 2025-09-02 上海萨丽斐生物科技有限公司 一种具有保湿、修护、紧致、抗皱功效的组合物及其应用

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0339285A3 (en) * 1988-03-31 1989-11-29 RORER INTERNATIONAL (OVERSEAS) INC. (a Delaware corporation) Recombinant endonexin ii
US5229367A (en) * 1991-01-21 1993-07-20 Sclavo S.P.A. Antiinflammatory peptide derived from human lipocortin V
NZ283171A (en) 1994-04-11 1998-02-26 Nexins Research Bv Detecting or quantifying apoptotic cells in a sample
US7645739B2 (en) * 2001-02-21 2010-01-12 Alavita Pharmaceuticals, Inc. Modified annexin compositions and methods of using same
US20030152513A1 (en) 2001-09-06 2003-08-14 Imetrix, Inc. Intravascular delivery of therapeutic and imaging agents to stressed and apoptotic cells using annexin V as a targeting vector
WO2003103577A2 (en) 2002-06-06 2003-12-18 Tze Chein Wun Novel recombinant anticoagulant proteins
WO2005099744A1 (en) 2004-04-15 2005-10-27 Athera Biotechnologies Ab Annexin v for preventing atherothrombois and plaque rupture
EP2173342A2 (en) 2007-06-22 2010-04-14 ETH Zurich Antivirals
MX2010001194A (es) * 2007-07-31 2010-07-30 Univ Louisiana State Conjugado de polipeptido-acido nucleico para inmunoprofilaxis o inmunoterapia para desordenes neoplasicos o infecciones.
EP2234631B1 (en) 2007-12-18 2012-09-12 Athera Biotechnologies AB Compounds and methods for the treatment of vascular disease
TR201909412T4 (tr) 2008-02-22 2019-07-22 Annexin Pharmaceuticals Ab Restenozun önlenmesi veya tedavisi için bileşikler ve yöntemler.
JP5590621B2 (ja) 2008-10-17 2014-09-17 ロンドン ヘルス サイエンシーズ センター リサーチ インコーポレイテッド 炎症性障害の処置を処置するためのアネキシンおよびその使用
MA41020A (fr) * 2014-11-25 2017-10-03 Evelo Biosciences Inc Compositions probiotiques et prébiotiques, et leurs procédés d'utilisation pour la modulation du microbiome

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
Annexin A5 as a novel player in prevention of atherothrombosis in SLE and in the general polulation;Cederholm等;《Ann.N.Y.acad.Sci.》;20070829;第1108卷(第1期);摘要、第98-100页 *
Inhibition of the interleukin-1β-induced pyresis in the rabbit by peptide 204-212 of lipocortin 5;Palmi等;《European journal of pharmacology》;19950701;第281卷(第1期);摘要、第98-99页 *
premature atherosclerotic cardiovascular disease in systemic lupus erythematosus;Westerweel等;《arthritis & rheumatism》;20070531;第56卷(第5期);第1384页左栏第1-10行 *
膜联蛋白A5与宫颈粘膜上皮细胞癌变的关系;李欣 等;《解剖学杂志》;20061231(第4期);433-435 *

Also Published As

Publication number Publication date
CA2740557C (en) 2020-04-14
EP2349321A4 (en) 2012-12-19
CN102256617A (zh) 2011-11-23
EP2349321A1 (en) 2011-08-03
JP2012505837A (ja) 2012-03-08
US20120014920A1 (en) 2012-01-19
CA2740557A1 (en) 2010-04-22
EP2349321B1 (en) 2020-04-22
WO2010043045A1 (en) 2010-04-22
JP5590621B2 (ja) 2014-09-17
US9192649B2 (en) 2015-11-24

Similar Documents

Publication Publication Date Title
CN102256617B (zh) 膜联蛋白及其治疗炎性病症的用途
US20230036788A1 (en) Compositions and methods of using tyrosine kinase inhibitors
Zicha et al. Sinus node dysfunction and hyperpolarization-activated (HCN) channel subunit remodeling in a canine heart failure model
JP2023511358A (ja) 線維化、肥大または心不全の処置または予防における使用のための骨髄由来増殖因子
Wang et al. Toll-like receptor 4 signaling confers cardiac protection against ischemic injury via inducible nitric oxide synthase-and soluble guanylate cyclase-dependent mechanisms
Ren et al. β3 Integrin deficiency promotes cardiac hypertrophy and inflammation
JP5221959B2 (ja) 代謝障害の状態を治療するためのｉｌ−２２の使用
CN106063928B (zh) 一种多肽或其衍生物在治疗高血压性心肌肥厚中的应用
Zhang et al. Cardiac ankyrin repeat protein contributes to dilated cardiomyopathy and heart failure
US20160206699A1 (en) Use of interleukin 10 mrna transfected macrophages in anti-inflammatory therapies
CN118252913B (zh) 多肽偶联物及其在射血分数保留的心衰中的应用
WO2012006585A2 (en) Use of interleukin-15 to treat cardiovascular diseases
CN102558357B (zh) 一种可以治疗心肌缺血再灌注损伤的p38α拮抗肽
US20090169540A1 (en) Use Of An Antagonist Of Epac For Treating Human Cardiac Hypertrophy
AU2015374240B2 (en) Compositions and methods for delivering lypophilic agents to dental pulp and for enhancing dentin production
US20210244827A1 (en) Anc80 encoding sphingolipid-metabolizing proteins
Huang et al. The lymphocyte adapter protein: a negative regulator of myocardial ischemia/reperfusion injury
Rainer et al. Cardiomyocyte-specific TGFβ suppression blocks neutrophil infiltration, augments multiple cytoprotective cascades, and reduces early mortality after myocardial infarction
CN104800829B (zh) 寡肽联合或与吗啡的组合在制备用于镇痛的药物中的用途
Abdelaziz The Protective Effects of Remote Ischaemic Preconditioning on Pressure Overload-Induced Myocardial Remodelling
Song et al. JAHA. 2021. pdf
Aleshina THE CORTICOSTATIC EFFECT OF HUMAN LACTOFERRIN DEPENDS ON THE AMINO ACID COMPOSITION OF THE N-TERMINUS OF THE MOLECULE
Jiang et al. Tspan9 Exacerbates Cardiac Hypertrophy by Impairing Cardiac Autophagy
TW202432141A (zh) 治療骨髓增生性腫瘤的方法
Song Effects of genetic manipulation of phospholamban protein levels on contractile function and remodeling in murine cardiac and slow-twitch skeletal muscles

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant